Prophylaxis with low-dose low molecular weight heparin during pregnancy and the puerperium: Is it effective? A rebuttal

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 6, 2011, Pages 1269-1271

  Patel, J P ^a,b   Patel, R K ^a   Davies, J G ^b   Arya, R ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

BODY WEIGHT; CLINICAL PROTOCOL; DEEP VEIN THROMBOSIS; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HETEROZYGOSITY; HIGH RISK PATIENT; HUMAN; LETTER; LOW DRUG DOSE; MATERNAL MORTALITY; PELVIC VEIN THROMBOSIS; PRACTICE GUIDELINE; PREGNANCY; PRENATAL PERIOD; PRESCRIPTION; PRIORITY JOURNAL; PUERPERIUM; TREATMENT DURATION; TREATMENT OUTCOME; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 79958051583     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04297.x     Document Type: Letter

References (12)

1. Roeters Van Lennep JE, Meijer E, Klumper FJCM, Middeldorp JM, Bloemenkamp KWM, Middeldorp S. Prophylaxis with low-dose low molecular weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemost 2011; 9: 473-80.
2. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008.
3. Lebaudy C, Hulot JS, Amoura Z, Costedoat-Chalumeau N, Serreau R, Ankri A, Conrad J, Cornet A, Dommergues M, Piette JC, Lechat P. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin Pharmacol Ther 2008; 84: 370-7.
4. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 844-86.
5. Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium. Guideline no. 37. London: RCOG Press, 2009.
6. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low molecular weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43: 1064-83.
7. Centre for Maternal and Child Enquiries (CMACE). Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. Br J Obstet Gynaecol 2011;118 (Suppl. 1):1-203.
8. Makatsaria AD, Bitsadze VO, Dolgushina NV. Use of the low-molecular weight heparin nadroparin during pregnancy. A review. Curr Med Res Opin 2003; 19: 4-12.
9. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GDO, Walker ID, Greaves M, Brenkel I, Regan L, Greer IA. Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2005; 132: 171-96.
10. Lindqvist P, Dahlbäck B, Marŝál K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595-9.
11. Hellgren M, Blomback M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest 1981; 12: 141-54.
12. Maybury HJ, Waugh JJS, Gornall A, Pavord S. There is a return to non-pregnant coagulation parameters after four not six weeks postpartum following spontaneous vaginal delivery. Obstet Med 2008; 1: 92-4.